AL
SNDX icon

Airain Ltd’s Syndax Pharmaceuticals SNDX Stock Holding History

Airain Ltd’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$150K Buy
+10,751
New +$123K 0.01% 775

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Airain Ltd's SNDX Position: Q2 2017 in Review

Airain Ltd opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2017: 10,751 shares worth $150K. The stake represents 0.01% of the portfolio and ranks #775 among its holdings.

66 funds tracked by Wall St. Rank hold SNDX as of Q2 2017.

  • Airain Ltd held 10,751 shares of Syndax Pharmaceuticals worth $150K as of Q2 2017.
  • Syndax Pharmaceuticals was a new Airain Ltd position in Q2 2017.
  • Syndax Pharmaceuticals made up 0.01% of Airain Ltd's portfolio in Q2 2017, its #775 holding.
  • 66 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.